WHO approved World’s first biosimilar Medicine

Question: World Health Organization (WHO) has approved first biosimilar medicine Trastuzumab. It will be used for the treatment of-
(a) Diabetes
(b) Breast Cancer
(c) TB
(d) Leukemia
Answer: (b)
Related facts:

  • On 18 December, 2019; The World Health Organization (WHO) has approved first biosimilar medicine.
  • This medicine named as Trastuzumab, is an injection to be used for breast cancer treatment.
  • It should be noted that biosimilar medicine is derived from living sources instead of the chemicals.
  • Noticeable that about 150,000 new patients is diagnosed with breast cancer every year in India.
  • Out of these nearly a fourth of the cases are HER2-positive and eligible for treatment with CANMAb (Trastuzumab)
  • The aim is to make breast cancer treatment affordable to women globally. This approval from WHO is first of such kind.

High efficacy of Trastuzumab:-

  • The Trastuzumab drug has proved high efficacy in curing early-stage breast cancer and in some cases more advanced forms of the disease.
  • Trastuzumab, made out of nonbio sources, costs about Rs 1400000 annually for the patients undergoing breast cancer treatment.
  • The high cost of the drug makes it out of reach of many women and healthcare systems in most countries
  • The biosimilar version of Trastuzumab is much cheaper than the original.
  • The drug is cheaper but equally effective biotherapeutic medicines are produced from biological sources such as cells rather than synthesized chemicals.

Production of Trastuzumab in India:

  • In January, 2014 Bangalore-based bio-pharmaceutical company Biocon launched the world’s first biosimilar (developed in an organism) Trastuzumab injection.
  • Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India and founded by Kiran Mazumdar-Shaw.
  • This was the first drug developed by Biocon in partnership with US-based generic drug maker Mylan.
  • The new drug Trastuzumab sold under the brand name CANMAb by the Biocon will be used to treat HER2-positive advanced breast cancer.
  • The drug has been jointly developed out of five molecules with Mylan, since a partnership was signed in 2009.
  • Mylan will also launch CANMab under a different brand in India.
  • The injection is available in 150mg and 440mg doses at Rs 19,500 and Rs 57,500, respectively.
  • The 440mg dose costs a fourth less than competing drugs, Mazumdar-Shaw said.

Links:
https://www.who.int/news-room/detail/18-12-2019-who-prequalifies-first-biosimilar-medicine-to-increase-worldwide-access-to-life-saving-breast-cancer-treatment
https://www.business-standard.com/article/companies/world-s-1st-biosimilar-drug-for-breast-cancer-114011800354_1.html